CertifiedTide.com
Back to Database

PT-141

Also known as: Bremelanotide, Vyleesi

Sexual Health
Approved

PT-141 (Bremelanotide) is the only FDA-approved melanocortin receptor agonist for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the nervous system rather than the vascular system.

Regulatory & Approval Status

FDA Approved

Bremelanotide is FDA-approved as Vyleesi for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.

Unlock the complete research profile

Create your free CertifiedTide account to access full compound details, mechanisms, safety data, and research tools.